Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Retrovirology · 2016 · PMC4818470 · PMID 27036656

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

borderline significantp = 0.07so close (0.05 < p ≤ 0.1)

A one sided Mann and Whitney test that compared the placebo and the 33 μg group showed that differences between the two were borderline significant (p = 0.07), while the two other vaccine groups yielded none significant differences (p > 0.1).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.